Company news: Corcept Therapeutics and Daiichi Sankyo

Share this article:

Corcept Therapeutics said Thursday its Cushing's syndrome drug will be launched April 11, three weeks earlier than expected. Korlym (mifepristone) will wholesale at $0.62 per milligram, or $186 per 300-mg tablet, VP of commercial operations Steven Lo told MM&M. The FDA approved the once-a-day treatment in February. It's the first FDA-sanctioned drug for the rare disease. Lo said the company had set an internal goal to have Korlym hit pharmacy shelves soon after April 8, which is Cushing's Awareness Day.

Daiichi Sankyo is starting April with a new global slogan: "Passion for Innovation. Compassion for Patients." It will be the first uniform slogan for the company since the 2006 merger which brought Daiichi Pharmaceutical and Sankyo under one roof. Marah Binder, DSI senior manager for corporate public relations, told MM&M that the slogan is part of a push toward a unified global image, and that the company had been sifting through iterations for more than a year. The new tagline will be slowly rolled out as of the first of the month.

Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

More in Business Briefs

Apple selfies spur diabetes donations

Jazz apples has launched a Crunch to Contribute campaign to raise money for one of two diabetes associations.

Baxter seeks Cambridge, Mass. HQ

Illinois may be tempted to offer tax incentives for the firm to stay put.

FDA wants Alexion to clean up

FDA inspectors have cited the manufacturer of the rare-disease drug Soliris (eculizumab) for poor manufacturing practices.